Megostat (Megestrol Acetate)

Megestrol acetate binds to progesterone receptors, providing progestogenic activity, and also exerts glucocorticoid‑like effects. This combination increases appetite, alters metabolism, and can suppress the growth of hormone‑sensitive cancer cells by modifying gene expression.

The dosage of Megostat is individualized and determined by the prescribing clinician based on the patient’s condition, weight, and response. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.

Safety data for Megostat in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Megostat (megestrol acetate) is a synthetic progestin with both appetite‑stimulating and hormone‑modulating properties, distinguishing it from agents like dronabinol or mirtazapine, which act primarily through cannabinoid or antihistaminic pathways. Its dual activity can be advantageous in cancer‑related cachexia and hormone‑sensitive tumors.

Megostat should be stored at ambient temperature below 25 °C, in its original container, protected from moisture, heat and direct sunlight. Keeping the product in a stable environment helps maintain its potency and safety.

Megostat is taken orally, typically as a tablet or capsule, with or without food as directed by the prescriber. The exact administration schedule should follow the healthcare professional’s guidance.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe allergic reactions, hyperglycemia, and adrenal insufficiency if the drug is stopped abruptly. Patients should be monitored closely for these complications.

Megostat is contraindicated in individuals with known hypersensitivity to megestrol acetate, active thromboembolic disease, uncontrolled diabetes, or severe liver impairment. It should also be used with caution in patients receiving other hormonal or glucocorticoid therapies.